Although the peptide GLP-1 RAs is not FDA-approved for the treatment of cardiovascular disease, the potential therapeutic pleiotropic effects of the peptide GLP-1 RAs in patients with cardiovascular disease may extend beyond the treatment of diabetes in the future.350. The gene discussed is GLP1R; the disease is diabetes mellitus.